MNOV

MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

MediciNova, Inc. (MNOV) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (C-). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.7
EV / EBITDA -3.7
Rev Growth YoY 240.6%
Gross Margin 37.7%
Price Return 3M 6.9%
Price Return 12M -13.0%
Catalyst Signal 0.00
Market Cap $68.9M
TTM Revenue $920.5K
Price / Sales 74.9
ROE -25.6%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (1.9) B- (3.1) B (3.2) C+ (2.6) C+ (2.7)
2026-11-06 C+ (2.5) C- (1.9) B- (3.1) B (3.4) C+ (2.7) C+ (2.7)
2026-10-30 C+ (2.6) C- (1.9) B- (3.1) B (3.5) C+ (2.7) C+ (2.7)
2026-10-23 C+ (2.6) C- (1.9) B- (3.1) A (4.3) C+ (2.6) B- (2.9)
2026-10-16 C+ (2.5) C- (1.9) B- (3.1) A (4.2) C+ (2.6) B- (2.9)
Page 1 of 5